Bharat Biotech says supply chains not impacted by Russia-Ukraine conflict
A few Indian pharmaceutical companies have a presence in Russia, exporting and selling medicines in the country. Sales to Russia between April and December last year reached $386 million, or 15% of the total exports to the country.
Advertisement
New Delhi: Indian vaccine maker Bharat Biotech said on Friday the Russia-Ukraine conflict had not impacted the company's supply chains so far.
Unlike several Western companies including McDonald's, Microsoft, Coca-Cola and Starbucks that have stopped sales or operations in Russia, no Indian company has publicly withdrawn from the region.
A few Indian pharmaceutical companies have a presence in Russia, exporting and selling medicines in the country. Sales to Russia between April and December last year reached $386 million, or 15% of the total exports to the country.
Read Also - Bharat Biotech to come up with TB vaccine
Dr. Reddy's Laboratories said on Wednesday it was focused on business continuity in and around Russia, while executives from Torrent Pharma and Zydus Lifesciences said they saw little or no sales impact due to the conflict.
Production of Bharat Biotech's homegrown COVID-19 vaccine Covaxin "has been fully indigenised, all (active pharmaceutical ingredients) and critical raw materials are manufactured within India," the company said in an emailed statement.
"This was always a strategic decision at Bharat Biotech to develop and commercialise technologies developed within India and to reduce dependence on external sources," it added.
Bharat Biotech's COVID-19 shot Covaxin has accounted for 16.5% of the nearly 1.80 billion vaccine doses that have been administered to the Indian population so far.
Bharat Biotech is a pioneering biotechnology company. The company is known for its R&D and manufacturing capabilities. The company's mission is to deliver affordable, safe and high-quality vaccines and bio-therapeutics that help people prevail over diseases. The company seeks to lead innovation in biotechnology in order to lead the fight against disease with a focus on emerging markets.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.